

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.
Email ID: bacilpha@yahoo.com Tel.: 22618452/22661541, Tel/Fax: 22618327

Unaudited Financial Results for the quarter ended 31st December 2012


(Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended 31/03/12 Audited
		31/12/12 Unaudited	30/09/12 Unaudited	31/12/11 Unaudited	31/12/12 Unaudited	31/12/11 Unaudited	
1	Income						
	a) Net Sales/Income from Operations	---	---	---	54.60	---	46.00
	b) Other Operating Income	---	---	---	---	---	---
	Total Income	---	---	---	54.60	---	46.00
2	Expenditure						
	a) Increase/decrease in stock and work in progress	---	---	-78	39.00	-78	39.00
	b) Consumption of raw materials	---	---	---	---	---	---
	c) Purchase of traded goods	---	---	78	---	78	---
	d) Employees cost	---	---	---	---	---	---
	e) Depreciation	0.02	0.02	---	0.05	---	---
	f) Other expenditure	4.36	3.75	2.75	11.99	5.00	7.19
	Total Expenditure	4.38	3.77	2.75	51.04	5.00	46.19
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	-4.38	-3.77	-2.75	3.56	-5.00	-0.19
4	Other Income	0.45	---	3.85	0.45	4.75	5.46
5	Profit before interest and Exceptional Items (3+4)	-3.93	-3.77	1.10	4.01	-0.25	5.27
6	Interest	---	---	---	---	---	---
7	Profit after Interest but before Exceptional Items (5-6)	-3.93	-3.77	1.10	4.01	-0.25	5.27
8	Exceptional items	---	---	---	---	---	---
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	-3.93	-3.77	1.10	4.01	-0.25	5.27
10	Tax expense	---	---	---	0.50	---	0.81
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	-3.93	-3.77	1.10	3.51	-0.25	4.46
12	Extraordinary Item (net of tax expense Rs. _____)	---	---	---	---	---	---
13	Net Profit(+)/ Loss(-) for the period (11-12)	-3.93	-3.77	1.10	3.51	-0.25	4.46
14	Paid-up equity share capital (F.V. Rs.10/- per share)	589.00	589.00	589.00	589.00	589.00	589.00
15	Reserve excluding Revaluation Reserves	---	---	---	---	---	---
16	Earnings Per Share (EPS)						
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	---	---	---	---	---	---
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	---	---	---	---	---	---
17	Public Shareholding						
	- No. of shares	33,76,300	33,76,300	33,76,300	33,76,300	33,76,300	33,76,300
	- Percentage of shareholding	57.32%	57.32%	57.32%	57.32%	57.32%	57.32%
18	Promoters and promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered						
	- Number of shares	25,13,700	25,13,700	25,13,700	25,13,700	25,13,700	25,13,700
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	42.68%	42.68%	42.68%	42.68%	42.68%	42.68%

Note:

- The above results were reviewed by audit committee and taken on record by the Board of Directors of the Company in its meeting held on February 15, 2013.
- The Statutory Auditors of the Company have conducted a "Limited Review" of the aforesaid results for the half year ended December 31, 2012.
- No activities were carried out at the plant of the company and the expenses pertaining to the said facility were included under the head project pre-operative expenses.
- There are no separate reportable segments.
- There are 2 investor complaints received and resolved at the end of quarter.

For BACIL PHARMA LIMITED


Director

Place: Mumbai
Dated: February 15, 2013

A. W. KETKAR & CO.
CHARTERED ACCOUNTANTS

4, "SOUKHYA",
Opp. B.M.C. Hospital
V. N. Purav Marg, Chunabhatti,
Mumbai 400 022

LIMITED REVIEW REPORT


Ref.: BACIL PHARMA LIMITED

"We have reviewed the accompanying statement of un-audited financial results of **BACIL PHARMA LIMITED** for the quarter ended 31st December, 2012. This statement is the responsibility of the Company's management and has been approved by the Board of Directors.

A review of interim financial information consists principally of applying analytical procedures for financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement".

For **A. W. KETKAR & CO.**
CHARTERED ACCOUNTANTS



W. KETKAR
Proprietor

Place : Mumbai
Dated: February 15, 2013